Table 1.

Summary of randomized clinical trials that assessed peri-operative or adjuvant chemotherapy in patients with metastatic colon cancer with resectable liver disease.

Trial	Number	Interventions	DFS	OS
Peri-operative chemotherapy
EORTC 40983 [21,36]	364	Peri-operative FOLFOX for 12 cycles vs. observation	3-year DFS rate 36.2 vs. 28.1% (HR 0.77, p = 0.041	Median OS 63.7 vs. 55 months (HR 0.84, p = 0.3)
Adjuvant chemotherapy
ENG Trial [50]	129	5FU/LV vs. observation	4-years DFS rate 45 vs. 35% (p = 0.35)	4-year OS rate 57 vs. 47% (p = 0.39)
FFCD trial [39]	173	5FU/LV vs. observation	5-year DFS 33.5 vs. 26.7% (p = 0.028)	5-year OS rate 51.1 vs. 41.1% (p = 0.13)
Ychou et al. [35]	321	FLOFIRI vs. 5FU/LV	Median PFS 24.7 vs. 21.6 months	3-year OS rate 72.7 vs. 71.6% (p = 0.028)
Hasegawa et al. [52]	180	Uracil-tegafur/LV vs. observation	3-year RFS 38.6 vs. 32.3% (HR 0.56, p = 0.003)	5-year OS 66.1 vs. 66.8%, HR 0.8, p = 0.4)
JCOG603 [37]	300	FOLFOX vs. observation	3-year DFS 52.1 vs. 41.5% (HR 0.63, p = 0.002)	5-year OS rate 69.5 vs. 83%

DFS: Disease-free survival; HR: hazard ratio; RFS: relapse-free survival; OS: overall survival.